Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024 07:05 ET
|
Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Shenandoah Telecommunications Company to Hold its First Quarter 2024 Earnings Call at 8:30 a.m. on Friday, May 3, 2024
April 24, 2024 07:00 ET
|
Shenandoah Telecommunications Co
Shentel Announces 1Q'24 Earnings Call
Smart Share Global Limited Files Its Annual Report on Form 20-F
April 24, 2024 07:00 ET
|
Smart Share Global Limited
SHANGHAI, April 24, 2024 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 24, 2024 07:00 ET
|
atai Life Sciences
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently...
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments
April 24, 2024 07:00 ET
|
Augmedix Inc
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go...
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
April 24, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Universal Stainless to Webcast First Quarter 2024 Results Conference Call on May 1st
April 24, 2024 07:00 ET
|
Universal Stainless & Alloy Products, Inc.
BRIDGEVILLE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Universal Stainless & Alloy Products, Inc. (Nasdaq: USAP) announced today that it will report financial results for the first quarter of 2024...
Satellite Applications Catapult trials Arqit Network Secure™
April 24, 2024 07:00 ET
|
Arqit
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today announced the successful trial deployment of Arqit’s Network...
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
April 24, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...